Search results
47 Results for 'Lung Disease'
- Technologies (4)
- Team (0)
- News (35)
- Events (0)
- Jobs (0)
- Publications (0)
- Multimedia (8)
Technologies 4
-
AAV-Engineering For Advanced Gene Therapy
Gene therapy with AAV (adeno-associated virus) as a delivery vehicle is a leading therapeutic modality for genetic disorders that is approved in Europe for the metabolic disease Familial Lipoprotein Lipase Deficiency. It is currently being tested in clinical trials in the U.S. to treat other rare conditions like the retinal Leber Congenital Amaurosis and the... -
Mechanically-Activated Drug Targeting Nanotechnology
The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies... -
Human Organs-on-Chips
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to... -
Microfluidic Hemostasis Monitor
The body’s ability to stop bleeding, also known as hemostasis, is critical for survival. For patients with blood clotting disorders, medical conditions requiring the use of anticoagulation or antiplatelet drugs, or who require treatment with extracorporeal devices that circulate their blood outside of the body, it is essential that care providers can rapidly monitor their...
News 35
Multimedia 8
-
Video/AnimationSmoking Human Lung Small Airway-on-a-ChipIn this video, Wyss Founding Director Donald Ingber and Technology Development Fellow Kambez Benam explain how the integrated smoking device mimics normal cigarette smoke exposure and how it can impact research into the causes of COPD and into new biomarkers and therapeutics. Credit: Wyss Institute at Harvard University -
Video/AnimationSmall Airway-on-a-Chip: Modeling COPD and AsthmaDevelopment of new therapeutics for chronic lung diseases have been hindered by the inability to study them in vitro. To address this challenge, Wyss Institute researchers used their Organ-on-a-Chip technology to produce a microfluidic ‘human lung small airway-on-a-chip.’ The device, which is composed a clear rubber material, is lined by living Human lung small airway... -
Video/AnimationHuman Organs-On-ChipsWyss Institute researchers and a multidisciplinary team of collaborators have engineered microchips that recapitulate the microarchitecture and functions of living human organs, including the lung, intestine, kidney, skin, bone marrow and blood-brain barrier. These microchips, called ‘organs-on-chips’, offer a potential alternative to traditional animal testing. Each individual organ-on-chip is composed of a clear flexible polymer... -
Video/AnimationNanoRx: Clot-Busting NanotherapeuticIn this animation, learn how the Wyss Institute clot-busting nanotherapeutic is activated by fluid high shear force – which occurs where blood flows through vessels narrowed by obstruction – to specifically target clots and dissolve them away. By pairing this drug with an intra-arterial device that restores blood flow to complete obstructions, the drug-device combination...
-
Video/AnimationResearchers mimic pulmonary edema in Lung-on-a-ChipThe Wyss Institute’s human breathing lung-on-a-chip, made using human lung and blood vessel cells, acts much like a lung in a human body. A vacuum re-creates the way the lungs physically expand and contract during breathing. As reported in Science Translational Medicine on November 7, 2012, Wyss researchers have now mimicked a human disease –... -
Video/AnimationClot-busting nanotherapeuticWyss Core Faculty member Donald E. Ingber describes the clot-busting nanotherapeutic. Credit: Wyss Institute at Harvard University